ALFA Finder| Revenue growth | FY26 revenue stagnant at ₹1,713cr; Q4 revenue ₹519cr. |
|---|---|
| Margins | Sequential EBITDA margin improvement to 20.3% in Q4. |
| Order book | Order book intact; healthy RFP activity in CDMO segments. |
| Demand visibility | Improving demand trends in Pharma; Crop Protection seeing inventory normalization. |
| Management confidence | Cautiously optimistic but defensive regarding USFDA and previous guidance misses. |
Growth
FY26 revenue of ₹1,713cr shows long-term stagnation; Q4 EBITDA margins improved to 20.3% sequentially.
Outlook
Targeting 5-6 DMF filings annually; FY27 guidance deferred to Q1 results due to geopolitical uncertainty.
Risks
USFDA warning letter at Bangalore site; high raw material volatility; major asset impairment at Panoli.
Earnings Call filed with BSE, NSE: HIKAL. Summary written with AI assistance from the document.
Hikal Ltd: key numbers
- Share price
- ₹224.52
- Market cap
- ₹2,768 Cr
- Revenue (annual)
- ₹1,713 Cr
- Net profit (annual)
- ₹-48.80 Cr
- P/E (TTM)
- -553.7×Sector 43.8×
- Promoter holding
- 68.85%+0.00% QoQ
- FII holding
- 1.28%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Hikal Ltd
All →Hikal Earnings Call Transcript: Key Takeaways
Q2 revenue ₹434 Cr, EBITDA ₹45 Cr (10.3%), PAT loss ₹6 Cr. H2 recovery claimed without a quantified bridge; FY guidance reiterated despite H1 loss.
Hikal Investor Presentation: Key Takeaways
Q2FY27 consolidated revenue ₹434 Cr (+36% YoY), EBITDA ₹45 Cr at 10.3% margin, PAT loss narrowed to ₹(6) Cr. Pharma led recovery; Crop Protection margins pressured.
Hikal Results Update
Hikal Ltd reported Q2 FY27 revenue of ₹434 Crore and an EBITDA of ₹45 Crore. The company also announced the commencement of commercial production for Personal Care at its Panoli facility.
- Value
- ₹434.0 Cr
Hikal Q2 FY27 Results: Net Loss of ₹6.1 Cr, Loss Narrows
Hikal Ltd reported revenue from operations of ₹434.2 Cr (+36.3% YoY) and a net loss of ₹6.1 Cr for Q2 FY27.
- Key figure
- Net loss ₹6.1 Cr
Hikal Bags New Order from Europe-based global agrochemical company
Hikal signed a multi-year CDMO contract with a Europe-based global agrochemical company for a specialised product. Commercial launch is expected towards the end of FY 2026-27.
- From
- Europe-based global agrochemical company (unnamed)
- Execution
- Multi-year
Hikal Regulatory Approval
Hikal's Bengaluru API facility received a Swissmedic GMP Certificate of Compliance. The certification supports wider access to European and other regulated markets.